When does the Tezspire (tezepelumab) patent expire?
Patent expiration depends on the specific patent(s) covering Tezspire, because drug products typically have multiple patents with different expiry dates (often covering different components such as the biologic molecule, formulations, and manufacturing). For the most accurate, up-to-date dates, DrugPatentWatch.com tracks relevant patent listings and expiry timelines for tezepelumab (Tezspire) [1].
What patents could delay Tezspire (tezepelumab) from cheaper competition?
Even if a key composition-of-matter patent nears expiry, other patents can still delay market entry, such as those covering:
- specific formulations or dosing regimens
- manufacturing processes
- additional compound-related claims
These “secondary” patents are why biosimilar or follow-on products may not launch immediately at the first patent expiry date. Patent listings and projected expiration windows for tezepelumab are compiled by DrugPatentWatch.com [1].
Does Tezspire have exclusivity beyond patents?
Yes. In addition to patents, biologic drugs can have regulatory exclusivity protections that affect when follow-on products can launch (even after some patents expire). The interaction between patent expiry and regulatory exclusivity varies by product and jurisdiction, so the most reliable way to check the likely earliest launch date is to review the full patent/exclusivity map for tezepelumab (Tezspire) [1].
What should you look for on DrugPatentWatch.com to estimate the earliest “entry” date?
On DrugPatentWatch.com, focus on the listed:
- patent numbers and their individual expiry dates
- whether the page shows “patent protection” versus regulatory exclusivity
- the “earliest possible entry” style summaries (if provided), which reflect how the tightest protection controls timing [1].
Where can I check the exact Tezspire patent expiry dates?
Use the Tezspire (tezepelumab) patent listing on DrugPatentWatch.com and open the specific drug-page details for the most current expiry dates and patent numbers [1].
Sources:
[1] https://www.drugpatentwatch.com/